Eszopiclone + Placebo control
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea
Conditions
Obstructive Sleep Apnea
Trial Timeline
Jan 1, 2008 → Feb 1, 2009
NCT ID
NCT00612157About Eszopiclone + Placebo control
Eszopiclone + Placebo control is a approved stage product being developed by Sumitomo Pharma for Obstructive Sleep Apnea. The current trial status is completed. This product is registered under clinical trial identifier NCT00612157. Target conditions include Obstructive Sleep Apnea.
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Sleep Apnea were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
✅Arformoterol Tartrate Inhalation Solution + Tiotropium + Arformoterol and Tiotropium + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00612157 | Approved | Completed |
Competing Products
20 competing products in Obstructive Sleep Apnea